Talzenna 1 mg hard capsules

DRUG3 trials

Sponsors

Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting, Hospices Civils De Lyon, Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Conditions

Adults subjects with advanced malignant pleural (cohort A) or peritoneal (cohorts B1 and B2) mesothelioma.Advanced solid tumorBreast cancerMultiple myelomaNon-Hodgkin lymphomaT-cell prolymphocytic leukemia

Phase 2

A Dutch National Study on behalf of the Center for Personalized Cancer Treatment (CPCT) to Facilitate Patient Access to Commercially Available, Targeted Anti-cancer Drugs to determine the Potential Efficacy in Treatment of Advanced Cancers with a Known Molecular Profile: The Drug Rediscovery Protocol (DRUP trial)

RecruitingCTIS2023-509152-33-00

Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis StichtingAdvanced solid tumor, Multiple myeloma, Non-Hodgkin lymphoma +1

Start: 2016-07-25Target: 3000Updated: 2025-12-19

TALAMESO : A Three-Cohort Phase II trial to Assess the Efficacy of a Maintenance Treatment with TALAzoparib following First Line Platinum-based Chemotherapy in Pleural or Malignant Peritoneal MESOthelioma Patients

RecruitingCTIS2024-514104-14-00

Hospices Civils De LyonAdults subjects with advanced malignant pleural (cohort A) or peritoneal (cohorts B1 and B2) mesothelioma.

Start: 2020-11-04Target: 40Updated: 2025-12-19

Phase 4

FUnctional selection of advanced breast cancer patients for Talazoparib treatment Using the REpair Capacity (RECAP) test: The FUTURE trial

CompletedCTIS2024-518036-36-03

Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)Breast cancer

Start: 2019-09-20End: 2025-04-22Target: 78Updated: 2025-01-31

Related Papers

Checkpoint Blockade Combinations in Tumor Mutational Burden/Load-High Tumors: Insights from the Atezolizumab + Bevacizumab and Nivolumab + Ipilimumab Cohorts in the Drug Rediscovery Protocol.

2025-12-01

Data from Checkpoint Blockade Combinations in Tumor Mutational Burden/Load-High Tumors: Insights from the Atezolizumab + Bevacizumab and Nivolumab + Ipilimumab Cohorts in the Drug Rediscovery Protocol

2025-12-01